---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-277601"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:37:22.077281+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BBOT Q3 2025 net loss $44.8M; cash $468.3M funds operations into 2028

## Summary
- Net loss of $44.8M vs $17.3M in Q3 2024; R&D expenses $35.1M, G&A $14.1M.
- Cash, equivalents and marketable securities $468.3M; runway expected into 2028.
- Closed SPAC business combination with Helix Acquisition Corp II on Aug 11, 2025; began trading on Nasdaq as BBOT.
- Appointed Uneek Mehra as CFO in July 2025.
- Three Phase 1 trials advancing (BBO-8520, BBO-10203, BBO-11818); initial clinical data readouts expected in 2026.

## SEC filing metadata
- accession: 0001193125-25-277601
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000119312525277601/0001193125-25-277601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000119312525277601/d814249d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-277601
- JSON: https://secwatch.observer/filing/0001193125-25-277601.json
- Plain text: https://secwatch.observer/filing/0001193125-25-277601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.